Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Proposed Q&A for Guidance on Biosimilars Released
June 15, 2009
- MAA for Alogliptin in the EU to Be Delayed Until 2012: Takeda
June 15, 2009
- Asahi Kasei to Enhance Focus on Pharma Business
June 15, 2009
- NDA for Au AA21004 Also to Be Delayed: Takeda
June 15, 2009
- Meiji Aims at Pharma Sales of ¥145.0 Bil. in FY2011
June 15, 2009
- R&D NEWS IN BRIEF
June 15, 2009
- Meiji Licenses out ME3301 to Amalyte
June 15, 2009
- Vero Cell-derived Japanese Encephalitis Vaccine Released
June 15, 2009
- JCR Pharmaceuticals Expects Launching of EPO Biosimilar in April 2010
June 15, 2009
- OPINION／Why Empathy Is Key in Closing
June 15, 2009
- GSK, Pola to Copromote GSK's 4 Topical Agents
June 15, 2009
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
June 15, 2009
- Combined Operating Profits of 21 JPMA Members Plummet 13.7%
June 15, 2009
- Kyokaikenpo to Distribute Generics Request Card to Help Patients Request Generics
June 15, 2009
- BUSINESS NEWS IN BRIEF
June 15, 2009
- MEDICAL DEVICE NEWS IN BRIEF
June 15, 2009
- Tsumura: Record-High Profits Focusing on Kampo Medicines
June 15, 2009
- Takeda to Launch New Series of OTC Drugs for GI Disorders
June 15, 2009
- Industry Leaders Advocate Price Cut Exemption for Innovative Drugs at Chuikyo
June 15, 2009
- FPMAJ Proposes Replacement of Cost Calculation Method with a New One
June 15, 2009
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…